Mural Oncology
Vijay Jayaprakash currently serves as the Senior Vice President of Clinical Development at Mural Oncology, managing Clinical Development, Clinical Pharmacology, Translational Medicine, and Patient Safety since July 2024. Prior to this role, Vijay held the position of Vice President of Clinical Development & Patient Safety at HUTCHMED, overseeing early asset portfolio development and leading programs for small molecule inhibitors in various cancers from November 2020 to July 2024. Vijay's extensive experience in clinical development includes significant roles at Bristol Myers Squibb, where leadership spanned multiple oncology programs, particularly in hematology, and at AstraZeneca, focusing on immuno-oncology registrational trials. Academic contributions include positions at Roswell Park Comprehensive Cancer Center and the University at Buffalo, with a strong background in cancer research and prevention. Educational credentials include degrees from the University at Buffalo, Tamil Nadu Dr. M.G.R. Medical University in Chennai, and the University of Washington.
Mural Oncology
2 followers
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)